Anticoagulant-Associated Intracerebral Hemorrhage

ABSTRACT

The incidence of anticoagulant-associated intracerebral hemorrhage (AAICH) quintupled during the 1990s, probably due to increased warfarin use for the treatment of atrial fibrillation. Anticoagulant-associated intracerebral hemorrhage now accounts for nearly 20% of all intracranial hemorrhage (ICH). Among patients using warfarin for atrial fibrillation, the annual risk of ICH in trials is 0.3 to 1.0%. Predictors of potential anticoagulant-associated hemorrhage are increasing age, prior ischemic stroke, hypertension, leukoaraiosis, the early period of warfarin use, higher intensity anticoagulation, and antiplatelet use in addition to anticoagulation. Compared with other intracranial hemorrhage patients, anticoagulated patients have a greater risk of hematoma expansion, subsequent clinical deterioration and death, necessitating vigorous reversal of their coagulopathy. Recommended methods of warfarin reversal are administration of intravenous vitamin K and either prothrombin complex concentrates or fresh frozen plasma. Reversal of unfractionated heparin is accomplished with intravenous protamine sulfate. Surgical treatment of intracranial hemorrhage may be life saving in select cases, but has not reduced morbidity or mortality in large randomized trials.

KEYWORDS

Intracerebral hemorrhage - anticoagulants - warfarin - epidemiology

REFERENCES

• 1 Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III.  Stroke. 1990;  21 (4) 637-676
• 2 Kleindorfer D O, Khoury J, Moomaw C J et al.. Stroke incidence is decreasing in whites but not in blacks: a population-based estimate of temporal trends in stroke incidence from the Greater Cincinnati/Northern Kentucky Stroke Study.  Stroke. 2010;  41 (7) 1326-1331
• 3 Flaherty M L, Haverbusch M, Sekar P et al.. Long-term mortality after intracerebral hemorrhage.  Neurology. 2006;  66 (8) 1182-1186
• 4 Dennis M S. Outcome after brain haemorrhage.  Cerebrovasc Dis. 2003;  16 (Suppl 1) 9-13
• 5 Kissela B, Schneider A, Kleindorfer D et al.. Stroke in a biracial population: the excess burden of stroke among blacks.  Stroke. 2004;  35 (2) 426-431
• 6 Flaherty M L, Woo D, Haverbusch M et al.. Racial variations in location and risk of intracerebral hemorrhage.  Stroke. 2005;  36 (5) 934-937
• 7 Fogelholm R, Nuutila M, Vuorela A L. Primary intracerebral haemorrhage in the Jyväskylä region, central Finland, 1985-89: incidence, case fatality rate, and functional outcome.  J Neurol Neurosurg Psychiatry. 1992;  55 (7) 546-552
• 8 Brown Jr R D, Whisnant J P, Sicks J D, O'Fallon W M, Wiebers D O. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989.  Stroke. 1996;  27 (3) 373-380
• 9 Tanaka H, Ueda Y, Date C et al.. Incidence of stroke in Shibata, Japan: 1976-1978.  Stroke. 1981;  12 (4) 460-466
• 10 Inagawa T, Ohbayashi N, Takechi A, Shibukawa M, Yahara K. Primary intracerebral hemorrhage in Izumo City, Japan: incidence rates and outcome in relation to the site of hemorrhage.  Neurosurgery. 2003;  53 (6) 1283-1297, discussion 1297–1298
• 11 Morgenstern L B, Smith M A, Lisabeth L D et al.. Excess stroke in Mexican Americans compared with non-Hispanic whites: the Brain Attack Surveillance in Corpus Christi Project.  Am J Epidemiol. 2004;  160 (4) 376-383
• 12 Labovitz D L, Halim A, Boden-Albala B, Hauser W A, Sacco R L. The incidence of deep and lobar intracerebral hemorrhage in whites, blacks, and Hispanics.  Neurology. 2005;  65 (4) 518-522
• 13 Woo D, Haverbusch M, Sekar P et al.. Effect of untreated hypertension on hemorrhagic stroke.  Stroke. 2004;  35 (7) 1703-1708
• 14 Woo D, Sauerbeck L R, Kissela B M et al.. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study.  Stroke. 2002;  33 (5) 1190-1195
• 15 Hemphill III J C, Bonovich D C, Besmertis L, Manley G T, Johnston S C. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage.  Stroke. 2001;  32 (4) 891-897
• 16 Broderick J P, Brott T G, Duldner J E, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.  Stroke. 1993;  24 (7) 987-993
• 17 Rosand J, Eckman M H, Knudsen K A, Singer D E, Greenberg S M. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.  Arch Intern Med. 2004;  164 (8) 880-884
• 18 Davis S M, Broderick J, Hennerici M Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage.  Neurology. 2006;  66 (8) 1175-1181
• 19 Leira R, Dávalos A, Silva Y Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society et al. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors.  Neurology. 2004;  63 (3) 461-467
• 20 Hart R G, Pearce L A, Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med. 2007;  146 (12) 857-867
• 21 Stafford R S, Singer D E. National patterns of warfarin use in atrial fibrillation.  Arch Intern Med. 1996;  156 (22) 2537-2541
• 22 Fang M C, Stafford R S, Ruskin J N, Singer D E. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation.  Arch Intern Med. 2004;  164 (1) 55-60
• 23 Flaherty M L, Kissela B, Woo D et al.. The increasing incidence of anticoagulant-associated intracerebral hemorrhage.  Neurology. 2007;  68 (2) 116-121
• 24 Kucher N, Castellanos L R, Quiroz R, Koo S, Fanikos J, Goldhaber S Z. Time trends in warfarin-associated hemorrhage.  Am J Cardiol. 2004;  94 (3) 403-406
• 25 Lawrentschuk N, Kariappa S, Kaye A H. Spontaneous intracerebral haemorrhages-warfarin as a risk factor.  J Clin Neurosci. 2003;  10 (5) 550-552
• 26 Flaherty M L, Haverbusch M, Sekar P et al.. Location and outcome of anticoagulant-associated intracerebral hemorrhage.  Neurocrit Care. 2006;  5 (3) 197-201
• 27 Hart R G, Boop B S, Anderson D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.  Stroke. 1995;  26 (8) 1471-1477
• 28 Hart R G, Tonarelli S B, Pearce L A. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.  Stroke. 2005;  36 (7) 1588-1593
• 29 Connolly S J, Ezekowitz M D, Yusuf S RE-LY Steering Committee and Investigators et al. Dabigatran versus warfarin in patients with atrial fibrillation.  N Engl J Med. 2009;  361 (12) 1139-1151
• 30 Mohr J P, Thompson J LP, Lazar R M Warfarin-Aspirin Recurrent Stroke Study Group et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.  N Engl J Med. 2001;  345 (20) 1444-1451
• 31 The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group . A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin.  Ann Neurol. 1997;  42 (6) 857-865
• 32 Gorter J W. For the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) and European Atrial Fibrillation Trial (EAFT) Study Groups . Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups.  Neurology. 1999;  53 (6) 1319-1327
• 33 Själander A, Engström G, Berntorp E, Svensson P. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population.  J Intern Med. 2003;  254 (5) 434-438
• 34 Petty G W, Brown Jr R DJ, Whisnant J P, Sicks J D, O'Fallon W M, Wiebers D O. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study.  Ann Intern Med. 1999;  130 (1) 14-22
• 35 Caro J J, Flegel K M, Orejuela M E, Kelley H E, Speckman J L, Migliaccio-Walle K. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice.  CMAJ. 1999;  161 (5) 493-497
• 36 Go A S, Hylek E M, Chang Y et al.. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?.  JAMA. 2003;  290 (20) 2685-2692
• 37 Hylek E M, Evans-Molina C, Shea C, Henault L E, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.  Circulation. 2007;  115 (21) 2689-2696
• 38 Fang M C, Chang Y, Hylek E M et al.. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.  Ann Intern Med. 2004;  141 (10) 745-752
• 39 The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group . A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin.  Ann Neurol. 1997;  42 (6) 857-865
• 40 Hart R G, Benavente O, Pearce L A. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis.  Cerebrovasc Dis. 1999;  9 (4) 215-217
• 41 Dentali F, Douketis J D, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials.  Arch Intern Med. 2007;  167 (2) 117-124
• 42 Flaker G C, Gruber M, Connolly S J SPORTIF Investigators et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.  Am Heart J. 2006;  152 (5) 967-973
• 43 Naka H, Nomura E, Wakabayashi S et al.. Frequency of asymptomatic microbleeds on T2*-weighted MR images of patients with recurrent stroke: association with combination of stroke subtypes and leukoaraiosis.  AJNR Am J Neuroradiol. 2004;  25 (5) 714-719
• 44 Jeerakathil T, Wolf P A, Beiser A et al.. Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study.  Stroke. 2004;  35 (8) 1831-1835
• 45 Greenberg S M, Finklestein S P, Schaefer P W. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI.  Neurology. 1996;  46 (6) 1751-1754
• 46 Roob G, Schmidt R, Kapeller P, Lechner A, Hartung H P, Fazekas F. MRI evidence of past cerebral microbleeds in a healthy elderly population.  Neurology. 1999;  52 (5) 991-994
• 47 Greenberg S M, Eng J A, Ning M, Smith E E, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage.  Stroke. 2004;  35 (6) 1415-1420
• 48 Lee S H, Ryu W S, Roh J K. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage.  Neurology. 2009;  72 (2) 171-176
• 49 Eckman M H, Wong L KS, Soo Y OY et al.. Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help?.  Stroke. 2008;  39 (12) 3308-3315
• 50 Pfleger M J, Hardee E P, Contant Jr C FJ, Hayman L A. Sensitivity and specificity of fluid-blood levels for coagulopathy in acute intracerebral hematomas.  AJNR Am J Neuroradiol. 1994;  15 (2) 217-223
• 51 Toyoda K, Okada Y, Ibayashi S et al.. Antithrombotic therapy and predilection for cerebellar hemorrhage.  Cerebrovasc Dis. 2007;  23 (2-3) 109-116
• 52 Flibotte J J, Hagan N, O'Donnell J, Greenberg S M, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage.  Neurology. 2004;  63 (6) 1059-1064
• 53 Rådberg J A, Olsson J E, Rådberg C T. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment.  Stroke. 1991;  22 (5) 571-576
• 54 Flaherty M L, Tao H, Haverbusch M et al.. Warfarin use leads to larger intracerebral hematomas.  Neurology. 2008;  71 (14) 1084-1089
• 55 Sjöblom L, Hårdemark H-G, Lindgren A et al.. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study.  Stroke. 2001;  32 (11) 2567-2574
• 56 Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P. CHANT Investigators . Hematoma growth in oral anticoagulant related intracerebral hemorrhage.  Stroke. 2008;  39 (11) 2993-2996
• 57 Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin.  Thromb Haemost. 2003;  89 (2) 278-283
• 58 Morgenstern L B, Hemphill J CI, Anderson C et al.. Guidelines for the management of spontaneous intracerebral hemorrhage. A guideline for healthcare professionals from the American Heart Association/American Stroke Association.  Stroke. 2010;  41 2108-2129
• 59 Anderson C S, Huang Y, Wang J G INTERACT Investigators et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial.  Lancet Neurol. 2008;  7 (5) 391-399
• 60 Hankey G J, Hon C. Surgery for primary intracerebral hemorrhage: is it safe and effective? A systematic review of case series and randomized trials.  Stroke. 1997;  28 (11) 2126-2132
• 61 Mendelow A D, Gregson B A, Fernandes H M STICH investigators et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial.  Lancet. 2005;  365 (9457) 387-397
• 62 Morgenstern L B, Demchuk A M, Kim D H, Frankowski R F, Grotta J C. Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage.  Neurology. 2001;  56 (10) 1294-1299
• 63 Mayer S A. Ultra-early hemostatic therapy for intracerebral hemorrhage.  Stroke. 2003;  34 (1) 224-229
• 64 Franchini M, Lippi G. Recombinant activated factor VII: mechanisms of action and current indications.  Semin Thromb Hemost. 2010;  36 (5) 485-492
• 65 Friederich P W, Henny C P, Messelink E J et al.. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial.  Lancet. 2003;  361 (9353) 201-205
• 66 Mayer S A, Brun N C, Begtrup K Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators et al. Recombinant activated factor VII for acute intracerebral hemorrhage.  N Engl J Med. 2005;  352 (8) 777-785
• 67 Mayer S A, Brun N C, Begtrup K FAST Trial Investigators et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.  N Engl J Med. 2008;  358 (20) 2127-2137
• 68 Diringer M N, Skolnick B E, Mayer S A et al.. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial.  Stroke. 2010;  41 (1) 48-53
• 69 Hanley J P. Warfarin reversal.  J Clin Pathol. 2004;  57 (11) 1132-1139
• 70 Ansell J, Hirsh J, Hylek E et al.. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 (6 Suppl) 160S-198S
• 71 Watson H G, Baglin T, Laidlaw S L, Makris M, Preston F E. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin.  Br J Haematol. 2001;  115 (1) 145-149
• 72 Fiore L D, Scola M A, Cantillon C E, Brophy M T. Anaphylactoid reactions to vitamin K.  J Thromb Thrombolysis. 2001;  11 (2) 175-183
• 73 Crowther M A, Douketis J D, Schnurr T et al.. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial.  Ann Intern Med. 2002;  137 (4) 251-254
• 74 Raj G, Kumar R, McKinney W P. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione.  Arch Intern Med. 1999;  159 (22) 2721-2724
• 75 Whitling A M, Bussey H I, Lyons R M. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation.  Arch Intern Med. 1998;  158 (19) 2136-2140
• 76 Flaherty M L, Adeoye O, Sekar P et al.. The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage.  Stroke. 2009;  40 (5) 1738-1742
• 77 Fredriksson K, Norrving B, Strömblad L G. Emergency reversal of anticoagulation after intracerebral hemorrhage.  Stroke. 1992;  23 (7) 972-977
• 78 Cartmill M, Dolan G, Byrne J L, Byrne P O. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies.  Br J Neurosurg. 2000;  14 (5) 458-461
• 79 Tanaka K A, Szlam F, Dickneite G, Levy J H. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.  Thromb Res. 2008;  122 (1) 117-123
• 80 Freeman W D, Brott T G, Barrett K M et al.. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage.  Mayo Clin Proc. 2004;  79 (12) 1495-1500
• 81 Robinson M T, Rabinstein A A, Meschia J F, Freeman W D. Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system.  Stroke. 2010;  41 (7) 1459-1463
• 82 Schulman S, Bijsterveld N R. Anticoagulants and their reversal.  Transfus Med Rev. 2007;  21 (1) 37-48
• 83 Hirsch J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 (3 Suppl) 188S-203S
• 84 Eikelboom J W, Weitz J I. New anticoagulants.  Circulation. 2010;  121 (13) 1523-1532
• 85 van Ryn J, Stangier J, Haertter S et al.. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.  Thromb Haemost. 2010;  103 (6) 1116-1127
• 86 Steiner T, Kaste M, Forsting M European Stroke Initiative Writing Committee et al. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage.  Cerebrovasc Dis. 2006;  22 (4) 294-316
• 87 Baglin T P, Keeling D M, Watson H G. British Committee for Standards in Haematology . Guidelines on oral anticoagulation (warfarin): third edition—2005 update.  Br J Haematol. 2006;  132 (3) 277-285
• 88 Baker R I, Coughlin P B, Gallus A S, Harper P L, Salem H H, Wood E M. Warfarin Reversal Consensus Group . Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis.  Med J Aust. 2004;  181 (9) 492-497